Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Christiane Knappmeyer is a leading translational researcher in gynecologic oncology, whose work centers on precision medicine for ovarian cancer. Her primary research areas include homologous recombination deficiency (HRD) as a predictive biomarker and the clinical implementation of next-generation sequencing to guide targeted therapy. In her landmark 2022 study, "Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort," Dr. Knappmeyer evaluated HRD status in 514 ovarian carcinoma samples using comprehensive DNA sequencing of BRCA1/BRCA2 and over 26,000 single-nucleotide polymorphisms. This work, cited over 40 times, demonstrated the feasibility and clinical utility of routine HRD testing in real-world settings, directly informing treatment decisions for patients with advanced ovarian cancer. Her contributions have helped bridge the gap between genomic discovery and bedside application, making personalized therapy more accessible. Dr. Knappmeyer’s research is instrumental in defining which patients may benefit from PARP inhibitors, ultimately improving outcomes in a disease with historically poor prognosis.